0001789769-21-000001.txt : 20210223 0001789769-21-000001.hdr.sgml : 20210223 20210223111023 ACCESSION NUMBER: 0001789769-21-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210223 DATE AS OF CHANGE: 20210223 EFFECTIVENESS DATE: 20210223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Instil Bio, Inc. CENTRAL INDEX KEY: 0001789769 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-390158 FILM NUMBER: 21663680 BUSINESS ADDRESS: STREET 1: 5949 SHERRY LANE STREET 2: SUITE 820 CITY: DALLAS STATE: TX ZIP: 75225 BUSINESS PHONE: 240-676-3715 MAIL ADDRESS: STREET 1: 5949 SHERRY LANE STREET 2: SUITE 820 CITY: DALLAS STATE: TX ZIP: 75225 D 1 primary_doc.xml X0708 D LIVE 0001789769 Instil Bio, Inc. 3963 Maple Avenue, Suite 350 DALLAS TX TEXAS 75219 240-676-3715 DELAWARE None None Corporation true 2018 Bronson Crouch c/o Instil Bio, Inc. 3963 Maple Avenue, Suite 350 Dallas TX TEXAS 75219 Executive Officer Director George Matcham c/o Instil Bio, Inc. 3963 Maple Avenue, Suite 350 Dallas TX TEXAS 75219 Director Kent McGaughy c/o Instil Bio, Inc. 3963 Maple Avenue, Suite 350 Dallas TX TEXAS 75219 Director Neil Gibson c/o Instil Bio, Inc. 3963 Maple Avenue, Suite 350 Dallas TX TEXAS 75219 Director Jack Nielsen c/o Instil Bio, Inc. 5949 Sherry Lane, Suite 820 Dallas TX TEXAS 75219 Director Nimish Shah c/o Instil Bio, Inc. 3963 Maple Avenue, Suite 350 Dallas TX TEXAS 75219 Director Gwen Binder c/o Instil Bio, Inc. 3963 Maple Avenue, Suite 350 Dallas TX TEXAS 75219 Director Sandeep Laumas c/o Instil Bio, Inc. 3963 Maple Avenue, Suite 350 Dallas TX TEXAS 75219 Executive Officer Biotechnology Decline to Disclose 06b false 2020-12-30 false true true Preferred Stock may convert to underlying shares of Common Stock. false 0 185449881 185449881 0 false 26 0 0 0 false Instil Bio, Inc. /s/ Bronson Crouch Bronson Crouch Chief Executive Officer 2021-02-21